Migraine Therapeutics Market Growth Factors, Segmentation, Trends, Opportunities, Key Players and Forecast | Evolve Business Intelligence

Key Highlights:
• The global Migraine Therapeutics Market size was valued at USD 1.8 billion in 2022 growing at a CAGR of 3.15% from 2023 to 2033.
• Asia Pacific dominated the market in 2022
• North America is expected to grow at the highest CAGR from 2023 to 2033

As per the study initiated by Evolve Business Intelligence, the global Migraine Therapeutics Market size accounted for USD 1.8 billion in 2022, growing at a CAGR of 3.15% from 2023 to 2033. The migraine therapeutics market refers to the pharmaceutical industry segment dedicated to the development and sale of medications specifically designed to treat migraines. It encompasses a range of drugs, including acute and preventive treatments, aiming to alleviate the symptoms and reduce the frequency of migraine attacks. Key players in the market focus on research and development to introduce innovative therapies, such as calcitonin gene-related peptide (CGRP) inhibitors. The market's growth is driven by the increasing prevalence of migraines, rising awareness, and a demand for more effective and targeted treatment options for this neurological
disorder.

Request/Download PDF Sample: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=021648

The migraine therapeutics market is primarily propelled by the growing prevalence of migraines worldwide. Increased awareness of migraine as a debilitating neurological condition and a rising demand for advanced and targeted treatment options contribute to market growth. Ongoing research and development, particularly in the field of CGRP inhibitors, play a crucial role in introducing innovative therapies, further driving the market.

Key Players
Some of the major Migraine Therapeutics Market players holding high market shares include Sanofi SA, Abbott Laboratories, Teva Pharmaceutical Industries Limited and Allergan Plc.These players use partnership and collaboration as a key strategy to gain significant market share to compete with market leaders. Some of the other major market players include Pfizer Inc, AstraZeneca, Johnson & Johnson, Endo International Plc, GlaxoSmithKline Plc, Impax Laboratories.

Report Description: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=021648

Segmental Analysis
Based on type, the Migraine Therapeutics market is segmented into Episodic and Chronic. In terms of revenue from the migraine market, the Episodic category retained a dominant position in 2022. For people who get one or two headaches a month, nonsteroidal anti-inflammatory medicines (NSAIDs) are prescribed and taken as soon as a migraine appears.
Based on Treatment Type, the Migraine Therapeutics market is segmented into Preventive and Abortive. The market was dominated by the Abortive sector in 2022, and during the forecast period of 2022-2030, it is anticipated to increase at a quicker rate.
Based on Drug Class, the Migraine Therapeutics market is segmented into Triptans, Ergots, and Others. Triptans held a dominant market position in 2022 and are anticipated to increase at the fastest rate throughout the 2022-2030 forecast period.

Key Region/ Countries Covered
• North America (US, Canada, Mexico)
• Europe (Germany, U.K., France, Italy, Spain, Russia, Nordic Countries, BeNeLux, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Rest of Asia Pacific)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, South Africa, Rest of MEA)
• Latin America (Mexico, Brazil, Argentina, Rest of Latin America)

Address
Evolve Business Intelligence
C-218, 2nd floor, M-Cube
Gujarat 396191
India
Email: sales@evolvebi.com
Website: https://evolvebi.com/

About EvolveBI
Evolve Business Intelligence is a market research, business intelligence, and advisory firm providing innovative solutions to challenging pain points of a business. Our market research reports include data useful to micro, small, medium, and large-scale enterprises. We provide solutions ranging from mere data collection to business advisory.
Evolve Business Intelligence is built on account of technology advancement providing highly accurate data through our in-house AI-modelled data analysis and forecast tool - EvolveBI. This tool tracks real-time data including, quarter performance, annual performance, and recent developments from fortune's global 2000 companies.

This release was published on openPR.